ECM
INO icon

ETrade Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

ETrade Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,048
Closed -$183K – 877
2020
Q1 		$183K Buy
+2,048
New +$126K ﹤0.01% 696

Other funds holding INO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

ETrade Capital Management's INO Position: Q2 2020 in Review

ETrade Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2020, closing a stake of 2,048 shares — an estimated $183K sold.

ETrade Capital Management first reported a position in INO in Q1 2020 and held it in 1 quarter. The position peaked at $183K in Q1 2020. 214 funds tracked by Wall St. Rank hold INO as of Q2 2020.

  • ETrade Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • ETrade Capital Management sold 2,048 Inovio Pharmaceuticals shares in Q2 2020, an estimated $183K.
  • ETrade Capital Management first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • ETrade Capital Management's Inovio Pharmaceuticals position peaked at $183K in Q1 2020.
  • 214 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2020.

Based on ETrade Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.